Trials / Withdrawn
WithdrawnNCT04674735
Safety of APSLXR in Patients Presenting Vertigo of Vestibular Origin or Meniere's Disease
Multicentre, Open Label, Phase I Clinical Trial to Evaluate the Safety of APSLXR for the Treatment of Vertigo of Vestibular Origin or Meniere's Disease
- Status
- Withdrawn
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Apsen Farmaceutica S.A. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety of APSLXR in participants with Meniere's disease or other Verigo of vestibular origin. Pharmacokinetics will also be evaluated in a small group.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | APSLXR | Oral coated tablets once a day for 60 days. |
Timeline
- Start date
- 2023-01-01
- Primary completion
- 2025-01-01
- Completion
- 2025-06-01
- First posted
- 2020-12-19
- Last updated
- 2022-04-26
Source: ClinicalTrials.gov record NCT04674735. Inclusion in this directory is not an endorsement.